Edition:
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

29.78USD
23 Feb 2017
Change (% chg)

$-0.14 (-0.47%)
Prev Close
$29.92
Open
$30.18
Day's High
$30.26
Day's Low
$29.35
Volume
298,211
Avg. Vol
456,947
52-wk High
$44.38
52-wk Low
$24.47

Latest Key Developments (Source: Significant Developments)

Emergent BioSolutions' board approves spin-off of Aptevo Therapeutics
Monday, 11 Jul 2016 07:00am EDT 

Emergent BioSolutions Inc. : Emergent Biosolutions' Board Of Directors Approves Spin Off of Aptevo Therapeutics and sets record and dividend distribution dates and distribution ratio . Expects to complete distribution of aptevo common stock to emergent stockholders on august 1, 2016. . Aptevo expects its common stock to begin trading on a "when issued" basis shortly before july 22, 2016 record date under ticker "apvo wi." . Aptevo has applied for listing on nasdaq global market. . On august 1, 2016, aptevo common stock is expected to begin "regular way" trading on nasdaq under symbol "apvo." .Emergent will continue to trade on new york stock exchange under ticker symbol "ebs.".  Full Article

Emergent BioSolutions says FDA completed pre-approval inspection of manufacturing facility for BioThrax
Tuesday, 21 Jun 2016 07:00am EDT 

Emergent BioSolutions Inc : Approval inspection of Emergent BioSolutions' large-scale manufacturing facility for BioThrax . Company received a no action indicated decision and no form 483 observations. .SBLA has a prescription drug user fee act (PDUFA) target action date of August 15, 2016.  Full Article

FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55
Friday, 17 Jun 2016 07:00am EDT 

Emergent Biosolutions : FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016 .FDA Accepts Emergent Biosolutions' Supplemental Biologics License Application For Large-Scale manufacturing of biothrax in building 55.  Full Article

Emergent Biosolutions Inc receives FDA orphan drug status for BioThrax
Wednesday, 15 Jun 2016 07:00am EDT 

Emergent BioSolutions Inc : Emergent BioSolutions Inc receives FDA orphan drug status for BioThrax for post-exposure prophylaxis of anthrax disease .Orphan drug status provides market exclusivity through November 2022, representing 7 years from date FDA approved pep indication for BioThrax.  Full Article

Emergent BioSolutions Inc gives FY 2016 outlook
Monday, 11 Jan 2016 07:01am EST 

Emergent BioSolutions Inc:Expects FY 2016 total revenues of $600 mln to $630 mln.Expects FY 2016 GAAP net income of $75 mln to $85 mln.Expects FY 2016 adjusted net income of $90 mln to $100 mln.Expects FY 2016 EBITDA of $150 mln to $160 mln.  Full Article

Emergent BioSolutions Inc announces plan to implement tax-free spin-off of biosciences business into a separate publicly-traded co
Thursday, 6 Aug 2015 07:01am EDT 

Emergent BioSolutions Inc:Announces plan to implement tax-free spin-off of biosciences business into a separate publicly-traded company.Board authorized co to pursue tax-free spin-off of co's biosciences business into separate, stand-alone publicly-traded co.Emergent expects to provide the biosciences company with a fixed cash contribution of $50 million to $70 million.Additional sources of cash to support research and development investment will include commercial product sales and partnership funding.Emergent to retain biodefense marketed products and development programs, platform technologies, manufacturing infrastructure.Says Emergent will maintain its headquarters in Gaithersburg, Maryland.Says expects to incur transaction-related expenses of $2 million to $4 million in 2015.Says company expects additional costs in 2016 leading up to completion of the spin-off.Says Daniel J. Abdun-nabi will remain president and CEO and robert G. Kramer will remain CFO of Emergent.Says Marvin L. white will serve as president and chief executive officer of the new biosciences company.  Full Article

Emergent BioSolutions Inc reaffirms FY 2015 guidance; gives Q3 2015 revenue guidance
Thursday, 6 Aug 2015 07:00am EDT 

Emergent BioSolutions Inc:Reaffirmed previous guidance for FY 2015.Expects FY 2015 total revenues of $510-$540 million, net income of $50-$60 million (GAAP) and $60-$70 million (adjusted).Expects Q3 2015 total revenues of $140 to $155 million.  Full Article

Emergent BioSolutions Inc awarded $19.7 million BARDA contract to develop and manufacture ebola monoclonal antibodies
Monday, 20 Jul 2015 07:00am EDT 

Emergent BioSolutions Inc:Says that it has been awarded contract by Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Ebola monoclonal antibodies.  Full Article

Emergent BioSolutions Inc signs long-term manufacturing agreement with Prometic Life Sciences
Tuesday, 19 May 2015 07:00am EDT 

Emergent BioSolutions Inc:Has signed strategic long-term manufacturing agreement with ProMetic Life Sciences Inc.This agreement provides ProMetic access to Emergent's cGMP FDA-licensed biopharmaceuticals facility located in Winnipeg, Manitoba, Canad.  Full Article

Emergent BioSolutions Inc reaffirms FY 2015 guidance; gives Q2 2015 revenue guidance
Thursday, 7 May 2015 04:28pm EDT 

Emergent BioSolutions Inc:Reaffirms FY 2015 financial outlook.Anticipates FY 2015 revenues of $510 to $540 million, net income of $50 to $60 million and adjusted net income of $60 to $70 million.Anticipates Q2 2015 total revenues of $105 to $120 million.  Full Article

More From Around the Web

BRIEF-Emergent Biosolutions reports Q4 EPS $0.67

* Fy2017 earnings per share view $2.08, revenue view $543.1 million -- Thomson Reuters I/B/E/S